Shanghai Youti Jisheng Biopharmaceutical

UT-Biomedicine is a clinical-stage biotechnology company based in Shanghai, China, dedicated to developing innovative CAR-T cell therapies for solid tumors. The company focuses on overcoming the barriers of the tumor microenvironment to enhance the therapeutic potential of immune cells against challenging malignancies. Its proprietary technology platform enables the design of next-generation cell products with improved infiltration and persistence. UT-Biomedicine's lead candidate, UT-001, is currently in clinical development for the treatment of hepatocellular carcinoma. Additionally, the company is advancing programs targeting Claudin 18.2 and Mesothelin for various gastrointestinal and solid cancers. Supported by leading venture capital investors, the firm aims to provide curative options for cancer patients globally.